This study demonstrated that cyclomethyline (2) and the corresponding enantiomers (R)-(-)-2 and (S)-(+)-2, displaying α2C-adrenoreceptor (AR) agonism/α2A-AR antagonism, similarly to
allyphenyline (1) and its enantiomers, significantly decreased the
naloxone-precipitated
withdrawal symptoms in mice at very low doses. It also highlighted that such positive effects on
morphine dependence can even be improved by additional serotoninergic
5-HT1A receptor (5-HT1A-R) activation. Indeed, 1 or the single (S)-(+)-1, 2, or both its enantiomers, all behaving as α2C-AR agonists/α2A-AR antagonists/5-HT1A-R agonists, alone and at the same low dose, improved
morphine withdrawal syndrome and exerted a potent
antidepressant-like effect. Therefore, considering the elevated comorbidity between
opiate abuse and depressed mood and the benefit of these multifunctional compounds to both disorders, it is possible that they prove more efficacious and less toxic than a cocktail of drugs in managing
opioid addiction.